

CRC Case	Sex	Order/Test	BMI	Histological Type	Location	Tumor Size (cm)	pTNM	Differentiation	Co-occurring GI Disorder
1	male	Expedited covid 19, CORONAVIRUS (S	21.1	adenocarcinoma	left		pT4		
2	female	two pre procedure and pre operative c	30.6	adenocarcinoma	left	0.7	pT1	well differentiated	
3	male	two pre procedure and pre operative c	22.1	adenocarcinoma	left		pT4	moderately differentiated	
4	female	expedited covid19	22.38	intramucosal adenocarcinoma	right				GERD
5	female	coronavirus (sars cov 2 access labs), p	21.5	adenocarcinoma	right	1	pT3	moderately differentiated	GERD
6	female	covid-19 PCR nasopharynx (bio-ref), C	30.12	adenocarcinoma	left	2.5	pT2		Ulcerative Colitis
9	male	expedited covid19	26.96	adenocarcinoma	right	3.5	pT3	moderately differentiated	GERD
10	male	pre procedure and pre operative covid	24.1	mixed neuroendocrine carcinoma-ade	left				
11	female	pre procedure and pre operative covid	23.9	adenocarcinoma	left		pT1	well differentiated	
12	male	pre procedure and pre operative covid	26	adenocarcinoma	left	1.5	pT4	moderately differentiated	
13	female	pre procedure and pre operative covid	37.5	adenocarcinoma	left	0.4	pT1	moderately differentiated	GERD
15	male	2019 coronavirus, coronavirus (sars co	24.13	adenocarcinoma	left	3.5	pT2	moderately differentiated	GERD
16	female	two pre procedure and pre operative c	25.99	adenocarcinoma	right	4	pT4	moderately differentiated	
17	male	coronavirus (sars cov 2 access labs), p	26.89	adenocarcinoma	left	1	pT1	moderately differentiated	GERD
18	male	coronavirus (sars cov 2 access labs), e	28.12	adenocarcinoma	left			moderately differentiated	
19	female	CCIRH rapid covid19, covid-19 PCR na	25.6	adenocarcinoma	left	5.5	pT3	moderately differentiated	
21	female	four 2019 coronavirus, expedited cov	24.2	adenocarcinoma	left	5.5	pT3	moderately differentiated	Type II Diabetes Mellitus
23	female	pre procedure and pre operative covid	19.77	signet-ring cell carcinoma	left	3	pT4	poorly differentiated	
24	male	two 2019 coronavirus, pre procedure	29.7	adenocarcinoma	left			moderately differentiated	
25	female	two pre procedure and pre operative c	25	adenocarcinoma	left	4.3	pT3	moderately differentiated	
26	male	covid-19 PCR nasopharynx (BIOREF)	28.94	adenocarcinoma	right	0.8		moderately differentiated	Type II Diabetes Mellitus
27	male	pre procedure and pre operative covid	32.2	adenocarcinoma	right	4.2	pT1	well differentiated	GERD
28	female	expedited covid19	29.1	mucinous adenocarcinoma	left	1.8	pT2		
29	male	pre procedure and pre operative covid	36.78	adenocarcinoma	right	0.4	pT3	well differentiated	GERD
30	male	pre procedure and pre operative covid	30.2	adenocarcinoma	right				GERD
31	female	pre procedure and pre operative covid	31.16	adenocarcinoma	right	4.5	pT2	moderately differentiated	
32	female	pre procedure and pre operative covid	23.6	adenocarcinoma	left			moderately differentiated	
33	female	three pre procedure and pre operative	19.1	squamous cell carcinoma	left	3.4	pT2	moderately differentiated	
34	male	pre procedure and pre operative covid	25.1	squamous cell carcinoma	left	0.4		moderately differentiated	
35	female	expedited covid19	23.68	neuroendocrine carcinoma	right	6	pT3	poorly differentiated	
36	female	expedited covid	28.3	adenocarcinoma	right	1.5	pT1	moderately differentiated	
37	female	coronavirus (sars cov 2 access labs)	22.3	adenocarcinoma	right	4.5	pT4	moderately differentiated	
38	female	covid19 PCR nasopharynx (BIOREF)	23.6	adenocarcinoma	left	5.5	pT3	well differentiated	
39	female	expedited covid19, coronavirus (sars	30.8	adenocarcinoma	left	3	pT2	well differentiated	Ulcerative Colitis
40	male	two coronavirus (sars cov 2 access lab)	28	mucinous adenocarcinoma	left	4.5	pT3		GERD
41	male	three coronavirus (sars cov 2 access lab	30.4	adenocarcinoma	left	0.3	pT3	moderately differentiated	Type II Diabetes Mellitus
42	female	coronavirus (sars cov 2 access labs), si	33.2	adenocarcinoma	left	0.7	pT2	moderately differentiated	
43	male	pre procedure and pre operative covid	27.1	squamous cell carcinoma	left	3	pT2	moderately differentiated	GERD
45	male	expedited covid19	23.7	adenocarcinoma	left	5.5	pT3	moderately differentiated	GERD
46	female	expedited covid19	24.24	mucinous adenocarcinoma	right	5	pT3	poorly differentiated	GERD
47	female	pre procedure and pre operative covid	28.91	adenocarcinoma	right	4.5	pT3	moderately differentiated	
48	male	expedited covid19	26.1	adenocarcinoma	right	1.5	pT2	moderately differentiated	
49	male	pre procedure and pre operative covid	26.2	adenocarcinoma	left	3	pT3	moderately differentiated	
55	male	coronavirus (sars cov 2 access labs), si	24.5	adenocarcinoma	left	3.5	pT3	moderately differentiated	Type II Diabetes Mellitus
56	male	2019 coronavirus, two coronavirus (s	30.4	adenocarcinoma	right	4	pT2	moderately differentiated	GERD
57	male	sars cov 2 rapid result antigen test	26.8	adenocarcinoma	left	2.5	pT1	moderately differentiated	
58	male	expedited covid19	27.12	adenocarcinoma	left	3	pT4	moderately differentiated	GERD
59	male	four sars-cov-2 molecular POCT covid	28.3	adenocarcinoma	left	4	pT3	poorly differentiated	
60	male	expedited covid19, two sars-cov-2 PC	28.9	adenocarcinoma	left	4	pT3	moderately differentiated	Type II Diabetes Mellitus
61	male	pre procedure and pre operative covid	30.4	adenocarcinoma	left	4.5	pT2	moderately differentiated	GERD
62	female	two sars-cov-2 RNA, pre procedure an	21.14	adenocarcinoma	left	2.5	pT3	moderately differentiated	
64	female	2019 coronavirus, three pre procedur	28.5	adenocarcinoma	left	4.5	pT3	poorly differentiated	
66	male	two sars-cov-2 RNA, expedited covid1	38.2	adenocarcinoma	left	5	pT3	moderately differentiated	Type II Diabetes Mellitus
68	male	expedited covid19, pre procedure anc	27.4	adenocarcinoma	left	3.5	pT3	moderately differentiated	GERD
69	male	expedited covid19, 2019 coronavirus	42.8	mucinous adenocarcinoma	right	5	pT3	moderately differentiated	
73	female	pre procedure and pre operative covid	48	adenocarcinoma	left	3	pT2	moderately differentiated	
75	male	2019 coronavirus, pre procedure and	20.5	adenocarcinoma	right	7	pT4	well differentiated	
76	male	2019 coronavirus	27.83	adenocarcinoma	right	7.5	pT3	moderately differentiated	GERD
77	male	pre procedure and pre operative covid	24.65	adenocarcinoma	left	7	pT4		
79	male	sars-cov-2 PCR	21.7	adenocarcinoma	left	3.2	pT2	moderately differentiated	
80	female	2019 coronavirus, coronavirus (sars co	27.21	adenocarcinoma	left	2	pT2	moderately differentiated	GERD
81	female	sars-cov-2 RNA, expedited covid19, c	24.55	adenocarcinoma	left				GERD
84	female	coronavirus (sars cov 2 access labs)	21.1	adenocarcinoma	left	7	pT4	poorly differentiated	
85	male	pre procedure and pre operative covid	30.5	adenocarcinoma	left	4.5	pT2	moderately differentiated	
93	female	2019 coronavirus, pre procedure and	20.98	adenocarcinoma	left	6	pT4	moderately differentiated	GERD
103	female	pre procedure and pre operative covid	19.9	adenocarcinoma	left	1.8	pT2	moderately differentiated	
113	male	expedited covid19, two sars cov 2 PCF	28.1	adenocarcinoma	right	8.5,2	pT3,pT1	moderately differentiated, well differe	Type II Diabetes Mellitus & GERD
114	male	expedited covid + flu A/B, four pre pr	31.74	adenocarcinoma	right	3.8	pT3	moderately differentiated	GERD
115	male	pre procedure and pre operative covid	27.67	adenocarcinoma	left	3	pT2	poorly differentiated	
117	male	pre procedure and pre operative covid	31.31	adenocarcinoma	right	4.5	pT4	moderately differentiated	GERD
119	male	expedited covid, expedited covid + flu	29.35	adenocarcinoma	left	2.5	pT2	poorly differentiated	
121	female	expedited covid19	24.4	adenocarcinoma	right	4.6	pT3	moderately differentiated	
124	male	two expedited covid19,	26.23	medullary carcinoma	right	11	pT3		
126	male	2019 coronavirus, pre operative and c	30	adenocarcinoma	left	3.5	pT3	poorly differentiated	type II Diabetes Mellitus & GERD
130	male	two expedited covid,	23	adenocarcinoma	right	10	pT3	moderately differentiated	
136	female	two expedited covid	18.11	adenocarcinoma	left	2	pT2	moderately differentiated	type II Diabetes Mellitus
137	female	pre procedure and pre operative covid	21.8	adenocarcinoma	right	1.5	pT1	moderately differentiated	
142	female	expedited covid19	24.8	adenocarcinoma	right	2.8	pT3	moderately differentiated	
146	male	three H&E/IHC stains, coronavirus (sa	28.3	adenocarcinoma	right	3.5	pT3	moderately differentiated	
149	male	expedited covid19	31.34	adenocarcinoma	left	2.5		poorly differentiated	GERD
152	male	two expedited covid19	23.47	adenocarcinoma	left	2	pT3		GERD
153	male	two 2019 coronavirus, covid19 PCR ni	27.67	adenocarcinoma	left	3.5	pT1	moderately differentiated	
161	female	two coronavirus (sars cov 2 access lab)	32.65	adenocarcinoma	left	2.5	pT2	moderately differentiated	GERD
164	female	coronavirus (sars cov 2 access labs), ts	24.8	adenocarcinoma	left	2.5	pT2	moderately differentiated	GERD
172	male	pre procedure and pre operative covid	29.07	adenocarcinoma	right	2.5	pT4		
178	male	two expedited covid19, two pre proce	26.05	adenocarcinoma	right	6.2	pT4	moderately differentiated	type II Diabetes Mellitus
179	female	expedited covid19, pre procedure anc	26.15	adenocarcinoma	left	4	pT4	moderately differentiated	GERD
181	male	sars-cov-2	26.62	adenocarcinoma	left	1	pT2	moderately differentiated	type II Diabetes Mellitus
182	female	expedited covid19, Sars-Cov-2	30.73	squamous cell carcinoma	left	2		poorly differentiated	
187	male	coronavirus (sars cov 2 access labs), e	24.74	adenocarcinoma	left	4.5	pT2	moderately differentiated	GERD
195	male	expedited covid19, two covid19 PCR,	18.19	adenocarcinoma	left	1.6	pT4		GERD
205	male	two expedited covid, two coronavirus	34.67	adenocarcinoma	right	0.3		moderately differentiated	
206	male	2019 coronavirus, expedited covid19	30.06	squamous cell carcinoma	left	10.2	pT3	moderately differentiated	GERD
207	female	two CCIRH rapid covid	25.9	adenocarcinoma	left	4.1	pT1	moderately differentiated	GERD
208	female	expedited covid, pre procedure and p	17.12	adenocarcinoma	left	5	pT2		GERD
211	male	coronavirus (sars cov 2 access lab) pre	21.8	adenocarcinoma	left			moderately differentiated	
215	male	three pre procedure and pre operative	34.31	adenocarcinoma	left	6	pT2	moderately differentiated	
217	male	expedited covid19, two coronavirus (s	22.78	adenocarcinoma	left	5	pT4	moderately differentiated	GERD
219	male	two expedited covid19, 2019 coronav	30.73	squamous cell carcinoma	left	4	pT4	moderately differentiated	type II Diabetes Mellitus
229	male	expedited covid19, rapid SARS-COV-2	31.2	adenocarcinoma	left	4.5	pT3	moderately differentiated	
239	female	pre procedure and pre operative covid	34.57	adenocarcinoma	left	0.1	pT1	well differentiated	